SEARCH:   Advanced

Blood, 1 November 2007, Vol. 110, No. 9, pp. 3456-3462. Prepublished online as a Blood First Edition Paper on July 25, 2007; DOI 10.1182/blood-2007-04-085969. This Article Full Text Full Text (PDF) All Versions of this Article: blood-2007-04-085969v1 110/9/3456    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Kebriaei, P. Articles by de Lima, M. Search for Related Content PubMed PubMed Citation Articles by Kebriaei, P. Articles by de Lima, M. Related Collections Transplantation Clinical Trials and Observations Neoplasia Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  TRANSPLANTATION Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia Partow Kebriaei1, Michelle A. Detry2, Sergio Giralt1, Antonio Carrasco-Yalan1, Athanasios Anagnostopoulos1, Daniel Couriel1, Issa F. Khouri1, Paolo Anderlini1, Chitra Hosing1, Amin Alousi1, Richard E. Champlin1, and Marcos de Lima1 Departments of1 Stem Cell Transplantation and Cellular Therapy and 2 Biostatistics, University of Texas M. D. Anderson Cancer Center, Houston, TX Allogeneic hematopoietic stem-cell transplantation (HSCT) remains an effective strategy for inducing durable remission in chronic myeloid leukemia (CML). Reduced-intensity conditioning (RIC) regimens extend HSCT to older patients and those with comorbidities who would otherwise not be suitable candidates for HSCT. The long-term efficacy of this approach is not established. We evaluated outcomes of 64 CML patients with advanced-phase disease (80% beyond first chronic phase), not eligible for myeloablative preparative regimens due to older age or comorbid conditions, who were treated with fludarabine-based RIC regimens. Donor type was matched related (n =30), 1 antigen-mismatched related (n =4), or matched unrelated (n =30). With median follow-up of 7 years, overall survival (OS) and progression-free survival (PFS) were 33% and 20%, respectively, at 5 years. Incidence of treatment-related mortality (TRM) was 33%, 39%, and 48% at 100 days, and 2 and 5 years after HSCT, respectively. In multivariate analysis, only disease stage at time of HSCT was significantly predictive for both OS and PFS. RIC HSCT provides adequate disease control in chronic-phase CML patients, but alternative treatment strategies need to be explored in patients with advanced disease. TRM rates are acceptable in this high-risk population but increase over time. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: L. K. Kenealy, C. B. Christenson, and C. B. Williams Current Therapies for Chronic Myeloid Leukemia Journal of Pharmacy Practice, April 1, 2008; 21(2): 116 - 125. [Abstract] [PDF]

	Blood Online is supported in part by Genentech BioOncology and Biogen Idec
	Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020